NCT06878404

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 552 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Conditions

• Arthritis, Psoriatic

Interventions

Type	Name	Description
DRUG	Icotrokinra	Icotrokinra will be administered.
DRUG	Placebo	Placebo will be administered.
DRUG	Active reference comparator	Active reference drug will be administered.

Timeline

• Start date: 2025-02-21
• Primary completion: 2026-05-27
• Completion: 2028-02-04
• First posted: 2025-03-17
• Last updated: 2026-04-13

Locations

155 sites across 16 countries: United States, Argentina, Australia, Bulgaria, China, Czechia, Denmark, Germany, Hong Kong, Hungary, India, Japan, Poland, Spain, Taiwan, Thailand

Regulatory

• FDA-regulated drug study